DENDRITIC CELL PROGENITORS PHAGOCYTOSE PARTICULATES, INCLUDING BACILLUS-CALMETTE-GUERIN ORGANISMS, AND SENSITIZE MICE TO MYCOBACTERIAL ANTIGENS IN-VIVO
K. Inaba et al., DENDRITIC CELL PROGENITORS PHAGOCYTOSE PARTICULATES, INCLUDING BACILLUS-CALMETTE-GUERIN ORGANISMS, AND SENSITIZE MICE TO MYCOBACTERIAL ANTIGENS IN-VIVO, The Journal of experimental medicine, 178(2), 1993, pp. 479-488
Dendritic cells, while effective in sensitizing T cells to several dif
ferent antigens, show little or no phagocytic activity. To the extent
that endocytosis is required for antigen processing and presentation,
it is not evident how dendritic cells would present particle-associate
d peptides. Evidence has now been obtained showing that progenitors to
dendritic cells can internalize particles, including Bacillus Calmett
e-Guerin (BCG) mycobacteria. The particulates are applied for 20 h to
bone marrow cultures that have been stimulated with granulocyte/macrop
hage colony-stimulating factor (GM-CSF) to induce aggregates of growin
g dendritic cells. Cells within these aggregates are clearly phagocyti
c. If the developing cultures are exposed to particles, washed, and ''
chased'' for 2 d, the number of major histocompatibility complex class
II-rich dendritic cells increases substantially and at least 50% cont
ain internalized mycobacteria or latex particles. The mycobacteria-lad
en, newly developed dendritic cells are much more potent in presenting
antigens to primed T cells than corresponding cultures of mature dend
ritic cells that are exposed to a pulse of organisms. A similar situat
ion exists when the BCG-charged dendritic cells are injected into the
footpad or blood stream of naive mice. Those dendritic cells that have
phagocytosed organisms induce the strongest T cell responses to mycob
acterial antigens in draining lymph node and spleen. The administratio
n of antigens to GM-CSF-induced, developing dendritic cells (by increa
sing both antigen uptake and cell numbers) will facilitate the use of
these antigen-presenting cells for active immunization in situ.